GSK acquires Elsie Biotechnologies for up to $50m to enhance oligonucleotide therapeutics
GSK plc (LSE/NYSE: GSK), a global healthcare leader, has completed the acquisition of Elsie Biotechnologies, a private biotechnology company based in San Diego, for a ... Read More
Johnson & Johnson to acquire Proteologix in $850m deal to enhance immunology portfolio
Johnson & Johnson (NYSE: JNJ) has entered into a definitive agreement to acquire Proteologix, Inc., a leading biotechnology company specializing in the development of bispecific ... Read More
RTW Biotech Opportunities joins $160.5m Series C of Obsidian Therapeutics
RTW Biotech Opportunities Ltd, an investment company listed on the London Stock Exchange and specialized in the life sciences sector, is proud to announce its ... Read More
4D Molecular Therapeutics secures $90m in Series B to advance gene therapy innovations
California-based 4D Molecular Therapeutics (4DMT), specializing in adeno-associated virus (AAV) gene therapy vector discovery and product development, has successfully raised $90 million through a Series ... Read More
Orchard Therapeutics raises $150m in Series C funding to advance gene therapies for rare diseases
Orchard Therapeutics, a leader in gene therapy specializing in rare diseases, has successfully secured $150 million through a Series C funding round. This substantial capital ... Read More